𝔖 Bobbio Scriptorium

✦ LIBER ✦

PCN88 AN ECONOMIC EVALUATION OF RITUXIMAB VERSUS OTHER FIRST-LINE TREATMENTS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND

✍ Scribed by P Kawalec; E Stawowczyk; M Russel-Szymczyk; M Szkultecka-Debek; R Aultman; E Carr; E Lech-Maranda; A Krawcewicz; M Wach; G Mazur

Book ID: 118611932
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 72 KB
Volume: 12
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)74339-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN92 Cost-Effectiveness of Nilotinib Ve

PCN92 Cost-Effectiveness of Nilotinib Versus Imatinib as First-Line Treatment for Newly Diagnosed Patients With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Russian Federation

✍ R. Yagudina; A. Kulikov; I. Komarov 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN57 Cost Effectiveness of Nilotinib Ve

PCN57 Cost Effectiveness of Nilotinib Versus Imatinib as First Line Treatment for Newly Diagnosed Hong Kong (HK) Patients With Chronic Phase, Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Hong Kong

✍ Tse, V.; Liu, H.; Botteman, M.; Mcghee, S.; Lee, V.W.; Lee, K.K. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB